8-K: Hepion Pharmaceuticals to Merge with Pharma Two B, Secures $11.5 Million Financing

Hepion Pharmaceuticals will merge with Pharma Two B, a late-clinical stage company developing a Parkinson's disease treatment, and secure $11.5 million in private financing.

Summary

• Hepion Pharmaceuticals is set to merge with Pharma Two B, a company focused on developing a treatment for Parkinson's disease.
• The merger will result in Pharma Two B becoming a publicly traded company, with current Pharma Two B equity holders owning approximately 85% of the combined company and current Hepion equity holders owning approximately 15% of the combined company, on a pro forma basis, subject to certain adjustments set forth in the merger agreement and prior to closing of the concurrent private financing.
• A concurrent private financing of $11.5 million will be completed immediately after the merger, with current Pharma Two B equity holders owning approximately 44.5% of the combined company, current Hepion equity holders owning approximately 7.8% of the combined company, and investors in the concurrent private financing owning approximately 47.7% of the combined company, in each case on a pro forma basis, subject to certain adjustments set forth in the merger agreement.
• Pharma Two B's lead product, P2B001, is a novel combination drug for Parkinson's disease, with an NDA submission targeted for the first half of 2026.
• Hepion has also secured $2.9 million through a private placement of senior unsecured notes, with $600,000 of the proceeds loaned to Pharma Two B.
• The merger is expected to close in the fourth quarter of 2024, pending stockholder and regulatory approvals.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the potential of the merger and the development of P2B001. However, there are some risks and uncertainties associated with the transaction, which temper the overall sentiment.

Positives

• The merger provides Pharma Two B with a path to becoming a publicly traded company.
• The combined company will have a focus on a promising Parkinson's disease treatment.
• The $11.5 million private financing will provide capital for the development of P2B001.
• The merger is expected to provide value to Hepion's stockholders.

Negatives

• Hepion's existing stockholders will have a reduced ownership stake in the combined company.
• The merger is subject to stockholder and regulatory approvals, which could delay or prevent the transaction.

Risks

• The merger may not be completed in a timely manner or at all.
• Pharma Two B may not meet Nasdaq initial listing standards.
• The combined company may not realize the anticipated benefits of the merger.
• There are risks associated with the development and commercialization of P2B001, including regulatory approval and market acceptance.
• The company will need to raise additional capital in the near term to continue operations.

Future Outlook

The combined company will focus on advancing P2B001 towards an NDA submission targeted for the first half of 2026 and making this potential treatment available to patients. The company will also seek to expand the label for P2B001.

Management Comments

• Dan Teleman, Chief Executive Officer of Pharma Two B, stated that P2B001 offers a novel therapeutic approach for Parkinson's disease and that the company is excited about its next growth phase.
• John Brancaccio, Executive Chairman of Hepion, believes the merger presents an excellent opportunity for Hepion's shareholders to become part of a company poised to file an NDA in a therapeutic area with a major unmet medical need.

Industry Context

The merger reflects a trend of pharmaceutical companies seeking to combine resources and expertise to develop and commercialize new treatments. The focus on Parkinson's disease addresses a significant unmet medical need in the neurological space.

Comparison to Industry Standards

• The merger is similar to other acquisitions in the biotech industry where a public company merges with a private company to gain access to a promising drug candidate and a path to public markets.
• The $11.5 million private placement is a common method for financing late-stage clinical development.
• The targeted NDA submission for P2B001 in the first half of 2026 is consistent with the timelines for other similar drug development programs.

Stakeholder Impact

• Hepion stockholders will receive ordinary shares of the combined company.
• Pharma Two B will gain access to public markets and additional capital.
• Patients with Parkinson's disease may benefit from the development of P2B001.

Next Steps

• Hepion stockholders will vote on the proposed merger.
• Pharma Two B will file a registration statement on Form F-4 with the SEC.
• The companies will work to satisfy all closing conditions for the merger.
• Pharma Two B will seek to list its ordinary shares on Nasdaq.
• Pharma Two B will advance the development of P2B001 towards an NDA submission.

Key Dates

Keywords

merger, Pharma Two B, Hepion Pharmaceuticals, Parkinson's disease, P2B001, private placement, NDA submission, biopharmaceutical, financing, Nasdaq